Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Gelsolin - BioAegis Therapeutics

Drug Profile

Gelsolin - BioAegis Therapeutics

Alternative Names: Gelsolin recombinant; hu r-P gelsolin; pGSN; Recombinant human plasma gelsolin; rh gelsolin; rhu-pGSN; Solinex

Latest Information Update: 30 Oct 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Brigham and Womens Hospital
  • Developer BioAegis Therapeutics; Critical Biologics Corporation
  • Class Anti-inflammatories; Antibacterials; Antifibrotics; Antineoplastics; Bronchodilators; Expectorants; Proteins
  • Mechanism of Action Protein replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Community-acquired pneumonia
  • Preclinical Pneumonia
  • Discontinued Bronchitis; Cystic fibrosis; Systemic inflammatory response syndrome

Most Recent Events

  • 22 Oct 2019 BioAegis Therapeutics plans a phase IIb trial for Pneumonia
  • 22 Aug 2019 Pharmacodynamics data from a preclinical studies in Pneumonia released by BioAegis Therapeutics
  • 02 Apr 2019 BioAegis Therapeutics completes a phase I/II trial in Community acquired pneumonia in Australia and Georgia (IV) (NCT03466073)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top